EL7.AI
StocksMedium•10 November 2026•
1 min read

Beam Therapeutics Shares Drop 10% Despite Successful Sickle Cell Trial Results

Key Facts

1The risto-cel therapy met its primary goal in a pivotal trial, freeing patients from severe vaso-occlusive crises for 12 consecutive months.
2Beam shares fell as much as 10% in Tuesday morning trading despite the positive clinical data.
3The company plans to submit an approval application to the FDA by the end of the year.

Beam Therapeutics shares fell as much as 10% in Tuesday morning trading on November 10, 2026, despite the company announcing successful pivotal trial results. BioPharma Dive reported that the risto-cel therapy met its primary goal by freeing patients from severe vaso-occlusive crises for 12 consecutive months. CEO John Evans stated that the data represents a defining milestone for the company's base editing technology.

The company plans to submit an approval application for the therapy to the FDA by the end of 2026. Beam Therapeutics will enter a competitive landscape against established therapies such as Lyfgenia and Casgevy, with the intraday share price decline potentially linked to 'sell the news' dynamics or concerns regarding future commercialization.

Open on chart